Combination treatment for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of two medicines (etentamig and pomalidomide) against standard treatments for people whose multiple myeloma has returned or not responded to therapy. The goal is to see if this combination works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has returned or not responded to previous treatment.
- You should have had 1 to 3 previous lines of therapy, and one of them must have included lenalidomide (Revlimid).
- Your organs must be working well enough, and you must be in generally good health.
- You cannot have had certain prior immunotherapy treatments that target BCMA, such as teclistamab or elranatamab.
- Your multiple myeloma must not have spread to the brain or spinal cord.
- You must not have had another active cancer in the past 3 years (with some exceptions), or serious medical conditions in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This trial tests a new combination of drugs (elotuzumab, isatuximab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with high-risk multiple myeloma. The goal is to see if this combination is safe and effective before and after a stem cell transplant.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This trial tests a new drug (BCD-248) combined with daratumumab for people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to see if this combination can help control the cancer better.
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.